Literature DB >> 28527009

The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value?

Kira Marie Voß1, Dorothee Cäcilia Spille1, Cristina Sauerland2, Eric Suero Molina1, Caroline Brokinkel3, Werner Paulus4, Walter Stummer1, Markus Holling1, Astrid Jeibmann4, Benjamin Brokinkel5.   

Abstract

In meningiomas, location-specific differences of the prognostic value of the Simpson classification are sparsely investigated but can influence strategy of surgery. We therefore compared the prognostic value of the Simpson classification in different tumor locations. Progression was compared with Simpson grade in 826 meningioma patients (median age 58 years, female:male ratio 2.4) in location-specific uni- and multivariate analyses. Simpson grade strongly correlated with tumor location (p < .001). Within a median follow-up of 50 months, recurrence was observed in 107 of 803 patients (13%). In general, increasing Simpson grade (p = .002) and subtotal resection (STR, ≥grade III) were correlated with tumor recurrence [hazard ratio (HR): 1.87; p = .004]. In 268 convexity meningiomas, frequency of tumor recurrence correlated with Simpson grade (p = .034). Risk of recurrence was similar after grade I and II resections, tended to increase after grade III (HR: 2.35; p = .087) but was higher after grade IV resections (HR: 7.35; p = .003). Risk of recurrence was higher after STR (HR: 4.21; p = .001) than after gross total resection (GTR, ≤grade II). Contrarily, increasing Simpson grade and STR were not correlated with progression in 102 falx, 38 posterior fossa and nine intraventricular meningiomas. In 325 skull base lesions, risk of recurrence was similar after GTR and STR (p = .198) and was only increased after grade IV resections (HR: 3.26; p = .017). Simpson grading and extent of resection were not equally prognostic in all locations. Lower impact of extent of resection should be considered during surgery for skull base, posterior fossa and falx meningiomas.

Entities:  

Keywords:  Location; Meningioma; Prognosis; Resection; Simpson classification

Mesh:

Year:  2017        PMID: 28527009     DOI: 10.1007/s11060-017-2481-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma.

Authors:  Anil Nanda; Shyamal C Bir; Tanmoy K Maiti; Subhas K Konar; Symeon Missios; Bharat Guthikonda
Journal:  J Neurosurg       Date:  2016-04-08       Impact factor: 5.115

2.  A multivariate analysis of prognostic factors for health-related quality of life in patients with surgically managed meningioma.

Authors:  Yifeng Miao; Xiaojie Lu; Yongming Qiu; Jiyao Jiang; Yuchang Lin
Journal:  J Clin Neurosci       Date:  2010-04       Impact factor: 1.961

3.  Radiological predictive factors for regrowth of residual benign meningiomas.

Authors:  Takatoshi Fujimoto; Yasuhito Ishida; Yoshitomo Uchiyama; Hiroyuki Nakase; Toshisuke Sakaki; Mitsutoshi Nakamura; Young-Su Park; Yasushi Motoyama; Fumihiko Nishimura
Journal:  Neurol Med Chir (Tokyo)       Date:  2011       Impact factor: 1.742

4.  Survival rates, prognostic factors and treatment of anaplastic meningiomas.

Authors:  Xiaoyu Cao; Shuyu Hao; Zhen Wu; Liang Wang; Guijun Jia; Liwei Zhang; Junting Zhang
Journal:  J Clin Neurosci       Date:  2015-03-28       Impact factor: 1.961

5.  Predictive factors related to symptomatic venous infarction after meningioma surgery.

Authors:  Woo-Youl Jang; Shin Jung; Tae-Young Jung; Kyung-Sub Moon; In-Young Kim
Journal:  Br J Neurosurg       Date:  2012-06-18       Impact factor: 1.596

Review 6.  Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases.

Authors:  Jan Frederick Cornelius; Philipp Jörg Slotty; Hans Jakob Steiger; Daniel Hänggi; Marc Polivka; Bernard George
Journal:  Acta Neurochir (Wien)       Date:  2013-01-15       Impact factor: 2.216

7.  Outcome comparison between younger and older patients undergoing intracranial meningioma resections.

Authors:  Michael Tin-Chung Poon; Linus Hing-Kai Fung; Jenny Kan-Suen Pu; Gilberto Ka-Kit Leung
Journal:  J Neurooncol       Date:  2013-06-05       Impact factor: 4.130

8.  Radiotherapy after surgery for benign cerebral meningioma.

Authors:  Serdar Soyuer; Eric L Chang; Ugur Selek; Weiming Shi; Moshe H Maor; Franco DeMonte
Journal:  Radiother Oncol       Date:  2004-04       Impact factor: 6.280

9.  Surgery for meningioma in the elderly and long-term survival: comparison with an age- and sex-matched general population and with younger patients.

Authors:  Benjamin Brokinkel; Markus Holling; Dorothee Cäcilia Spille; Katharina Heß; Cristina Sauerland; Caroline Bleimüller; Werner Paulus; Johannes Wölfer; Walter Stummer
Journal:  J Neurosurg       Date:  2016-06-03       Impact factor: 5.115

10.  Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.

Authors:  Walter Stummer; Thomas Meinel; Christian Ewelt; Peter Martus; Olga Jakobs; Jörg Felsberg; Guido Reifenberger
Journal:  J Neurooncol       Date:  2012-02-04       Impact factor: 4.130

View more
  34 in total

1.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

Review 2.  The Role of Surgery in Meningiomas.

Authors:  Michele Bailo; Filippo Gagliardi; Nicola Boari; Antonella Castellano; Alfio Spina; Pietro Mortini
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.598

3.  Meningioma recurrence rates following treatment: a systematic analysis.

Authors:  Victor Lam Shin Cheung; Albert Kim; Arjun Sahgal; Sunit Das
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

4.  WHO grade I meningiomas: classification-tree for prognostic factors of survival.

Authors:  Jean-Michel Lemée; Holger Joswig; Michele Da Broi; Marco Vincenzo Corniola; David Scheie; Karl Schaller; Eirik Helseth; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2019-06-10       Impact factor: 3.042

5.  Simpson grade IV resections of skull base meningiomas: does the postoperative tumor volume impact progression?

Authors:  Benjamin Brokinkel; Walter Stummer; Peter Sporns
Journal:  J Neurooncol       Date:  2017-12-14       Impact factor: 4.130

6.  Prediction of progression in skull base meningiomas: additional benefits of apparent diffusion coefficient value.

Authors:  Ching-Chung Ko; Sher-Wei Lim; Tai-Yuan Chen; Jeon-Hor Chen; Chien-Feng Li; Yow-Ling Shiue
Journal:  J Neurooncol       Date:  2018-01-20       Impact factor: 4.130

7.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

8.  Value of K i -67 Labeling Index in Predicting Recurrence of WHO Grade I Cranial Base Meningiomas.

Authors:  Jose Gabrielle Matias; Ignacio Jusue-Torres; Brendan Martin; Ankush Bajaj; Ewa Borys; Edward Melian; Kevin Barton; Douglas E Anderson; Vikram C Prabhu
Journal:  J Neurol Surg B Skull Base       Date:  2018-09-06

9.  Combined Extradural and Intradural Pterional Transzygomatic Approach to Large Sphenoid Wing Meningiomas. Operative Technique and Surgical Results.

Authors:  José M González-Darder
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-21

10.  Brain invasion in meningiomas: does surgical sampling impact specimen characteristics and histology?

Authors:  Maximilian Timme; Christian Thomas; Dorothee Cäcilia Spille; Walter Stummer; Heinrich Ebel; Christian Ewelt; Franz-Josef Hans; Uta Schick; Maximilian Puchner; Uwe Wildförster; Bernhard Bruns; Hans Axel Trost; Markus Holling; Oliver Grauer; Katharina Hess; Benjamin Brokinkel
Journal:  Neurosurg Rev       Date:  2019-06-03       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.